Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

16 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

New protein substance could be used to diagnose Alzheimer's disease

Gothenburg researchers have discovered a previously unknown substance in spinal fluid that can be used to diagnose Alzheimer's disease. The findings, described in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden, will also be useful in research on new medications.

15 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA

The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.

From Quest Diagnostics 14 Sep 2009

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.

11 Sep 2009

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.

11 Sep 2009

Biomarker Discovery Service from Arrayit to unravel mystery of genetic links for human disease states

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service.

11 Sep 2009

GENova Biotherapeutics to obtain three new drug target patents

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

11 Sep 2009

Biomarkers for rapid identification of treatment effectiveness in major depression

Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.

11 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company whose personalized oncology services division assists physicians by providing personalized treatment options for their cancer patients, has entered into a collaboration agreement with PinnacleCare, the pioneer and the leading private health advisory company in the world.

10 Sep 2009

Aushon BioSystems completes construction of new laboratory and manufacturing facility

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that it has completed the renovation and expansion of its Billerica, MA corporate headquarters.

10 Sep 2009

Lead exposure may result in cardiovascular mortality

Growing evidence shows that exposure to lead in the environment is associated with cardiovascular disease, including increased risk of hypertension. However, those studies have looked at lead concentrations in blood, not bone lead, a better indicator of cumulative lead exposure over time.

10 Sep 2009

Aperio Technologies forges alliance with HistoRx to provide an integrated whole-slide imaging system

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, and HistoRx, Inc., (HistoRx), a leader in the emerging field of tissue-based assays for targeted patient treatment, have entered into a partnership to provide an integrated solution for whole-slide imaging with fluorescence.

10 Sep 2009

ADDF's grant to Abiant for developing accurate imaging diagnostic approach

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $200,000 to Abiant, Inc. (Deerfield, IL), for the development of a highly accurate imaging diagnostic for Alzheimer's Disease.

9 Sep 2009

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

9 Sep 2009

AST scientific conference to emphasize on immunosuppression and tolerance

The American Society of Transplantation (AST) will present a scientific conference this winter that offers an in-depth, up-to-date look at immunosuppression and tolerance -- but with a brand new vibe. Called the Annual Scientific Exchange (ASE), slated for December 2-6, 2009, at the Marriott World Center in Orlando, Florida, it will differ from the typical conference in its format, which is specifically designed to be relaxed yet focused.

9 Sep 2009

Cell Biosciences acquires Alpha Innotech for $17.9 million

Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.

9 Sep 2009

Biomarker News and Research

Further Reading

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

New protein substance could be used to diagnose Alzheimer's disease

Altair announces positive Phase I results for AIR645 in treating asthma

GENova to file for Prostaganin patents in the US and in Europe

Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Biomarker Discovery Service from Arrayit to unravel mystery of genetic links for human disease states

GENova Biotherapeutics to obtain three new drug target patents

Biomarkers for rapid identification of treatment effectiveness in major depression

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Aushon BioSystems completes construction of new laboratory and manufacturing facility

Lead exposure may result in cardiovascular mortality

Aperio Technologies forges alliance with HistoRx to provide an integrated whole-slide imaging system

ADDF's grant to Abiant for developing accurate imaging diagnostic approach

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

AST scientific conference to emphasize on immunosuppression and tolerance

Cell Biosciences acquires Alpha Innotech for $17.9 million

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo